title: Human T lymphotropic virus type 1 infection influences hepatitis C virus clearance.
abstract: To explore the effect of human T lymphotropic virus type 1 (HTLV-1) infection on hepatitis C virus (HCV) infection, a survey for these viral infections was conducted that involved 2280 residents in an area in which HTLV-1 and HCV are endemic. The response of patients with HCV and HTLV-1 to interferon (IFN)-alpha treatment was also assessed. Antibody to HCV was detected in 13.8% of the residents tested, and antibody to HTLV-1 was detected in 15.4%. The prevalence of HCV RNA was significantly higher among residents who had antibodies to both HCV and HTLV-1 than in those who had antibodies to HCV only (P<.05). Sustained elimination of HCV RNA by IFN was significantly more frequent among patients with HCV alone than among those with HCV and HTLV-1. By logistic regression analysis, HTLV-1 infection was associated with nonresponse to IFN treatment. Thus, HTLV-1 infection affects the clearance, both natural and in association with IFN treatment, of HCV.
authors.affiliation: Department of Environmental Medicine and Infectious Disease, Faculty of Medical Sciences, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kishihara
authors.forename: N
authors.initials: N
authors.lastname: Furusyo
authors.forename: K
authors.initials: K
authors.lastname: Kashiwagi
authors.forename: A
authors.initials: A
authors.lastname: Mitsutake
authors.forename: S
authors.initials: S
authors.lastname: Kashiwagi
authors.forename: J
authors.initials: J
authors.lastname: Hayashi
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D005260:Female; D015481:HTLV-I Antibodies / Q000097:blood; D015490:HTLV-I Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology; D016174:Hepacivirus / Q000276:immunology / Q000302:isolation & purification*; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology; D018937:Hepatitis C Antibodies / Q000097:blood; D015368:Human T-lymphotropic virus 1 / Q000276:immunology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012367:RNA, Viral / Q000097:blood*; D017678:Sex Distribution; D016896:Treatment Outcome
chemical_list: D015481:HTLV-I Antibodies; D018937:Hepatitis C Antibodies; D016898:Interferon-alpha; D012367:RNA, Viral